Gilead Sciences presents five-year Phase II ZUMA-5 trial results for Yescarta in relapsed non-Hodgkin lymphomas, showing a 90 ...

Galapagos' CAR-T therapy GLPG5101 shows promise but faces challenges with limited data, cash reserves, and competition in the ...

CAR T-cell Therapy is expected to be the highest revenue-generating segment, projected to grow at a CAGR of 28.6% from 2023 to 2033. CA ...

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta®(axicabtagene ciloleucel) that demonstrate improved outcomes for people living with ...

This early data has demonstrated a clear improvement in GLPG5101 efficacy over its competitors in iNHL and MCL.

Therefore, it is similar in principle to the approved CAR T-cell therapies used in cancer therapy, such as Kymriah and ...

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

There are two cell therapies approved in this patient setting, Johnson & Johnson’s Carvykti and Bristol Myers Squibb's Abecma ...

Gilead Sciences, Inc. GILD announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European ...

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...

Oswald: Down the Rabbit Hole announces that Tik-Tok fame creator & actress Nora Freetly has been cast in next year's horror ...